

**WISP1 Antibody (Center) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP6255a****Specification**

---

**WISP1 Antibody (Center) Blocking Peptide - Product Information**

Primary Accession [O95388](#)  
Other Accession [WISP1\\_HUMAN](#)

**WISP1 Antibody (Center) Blocking Peptide - Additional Information**

**Gene ID** 8840

**Other Names**

WNT1-inducible-signaling pathway protein 1, WISP-1, CCN family member 4, Wnt-1-induced secreted protein, WISP1, CCN4

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6255a](/product/products/AP6255a) was selected from the Center region of human WISP1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**WISP1 Antibody (Center) Blocking Peptide - Protein Information**

**Name** CCN4 ([HGNC:12769](#))

**Synonyms** WISP1

**Function**

Downstream regulator in the Wnt/Frizzled-signaling pathway. Associated with cell survival. Attenuates p53-mediated apoptosis in response to DNA damage through activation of AKT kinase. Up-regulates the anti-apoptotic Bcl-X(L) protein. Adheres to skin and melanoma fibroblasts. In vitro binding to skin fibroblasts occurs through the proteoglycans, decorin and biglycan.

**Cellular Location**

Secreted.

**Tissue Location**

Expressed in heart, kidney, lung, pancreas, placenta, ovary, small intestine and spleen. Isoform 2 is expressed predominantly in scirrhous gastric carcinoma and, weakly in placenta. Overexpression is associated with several cancers including breast cancer and colon tumors. Isoform 2 is overexpressed in scirrhous gastric carcinoma

**WISP1 Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**WISP1 Antibody (Center) Blocking Peptide - Images****WISP1 Antibody (Center) Blocking Peptide - Background**

Wisp1 is a member of the WNT1 inducible signaling pathway (WISP) protein subfamily, which belongs to the connective tissue growth factor (CTGF) family. WNT1 is a member of a family of cysteine-rich, glycosylated signaling proteins that mediate diverse developmental processes. The CTGF family members are characterized by four conserved cysteine-rich domains: insulin-like growth factor-binding domain, von Willebrand factor type C module, thrombospondin domain and C-terminal cystine knot-like domain. Wisp1 may be downstream in the WNT1 signaling pathway that is relevant to malignant transformation. It is expressed at a high level in fibroblast cells, and overexpressed in colon tumors. The encoded protein binds to decorin and biglycan, two members of a family of small leucine-rich proteoglycans present in the extracellular matrix of connective tissue, and possibly prevents the inhibitory activity of decorin and biglycan in tumor cell proliferation. It also attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. It is 83% identical to the mouse protein at the amino acid level.

**WISP1 Antibody (Center) Blocking Peptide - References**

Hocevar, B.A., et al., EMBO J. 22(12):3084-3094 (2003). Tanaka, S., et al., Hepatology 37(5):1122-1129 (2003). Soon, L.L., et al., J. Biol. Chem. 278(13):11465-11470 (2003). Su, F., et al., Genes Dev. 16(1):46-57 (2002). Xie, D., et al., Cancer Res. 61(24):8917-8923 (2001).